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Significance of Study
• This study establishes a positive association between colorectal polyps and thyroid nodules. According 
to our analysis, this association seems to be independent from insulin resistance, which was previ-
ously argued to be a possible central mechanism in both disorders.
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Abstract
Objective: Colorectal polyps and thyroid nodules are com-
mon disorders linked to hyperinsulinemia and metabolic 
syndrome (Mets). The direct association between these two 
diseases is not clear. We aimed to analyze the prevalence of 
thyroid nodules in subjects with and without colorectal pol-
yps. The secondary aim was to establish the prevalence of 
Mets and its parameters in both disorders and to determine 
if insulin resistance and hyperinsulinemia are common 
underlying pathophysiological mechanisms. Subjects and 
Methods: One hundred and five subjects with colorectal pol-
yps (71 males, 34 females) and 68 controls (28 males, 40 fe-
males) were enrolled. The parameters of Mets together with 
TSH, insulin, low-density lipoprotein cholesterol, and ho-
meostasis model for assessment of insulin resistance levels 
were calculated. We performed thyroid ultrasonography in 
all participants. Results: The prevalence of Mets was similar 
in the colorectal polyp and control groups (37.1 vs. 37.3%, 
p = 0.982). The prevalence of Mets was nonsignificantly high-
er in subjects with a documented thyroid nodule compared 
to subjects without a thyroid nodule (43.0 vs. 32.6%, p = 
0.205). The prevalence of thyroid nodules in subjects with 
colorectal polyps was significantly higher than in subjects 
without polyps (52.9 vs. 35.3%, p = 0.017). Compared to sub-
jects with no colorectal polyps, we established a significant 
increase in the odds of having thyroid nodules (OR 2.05; 95% 
CI: 1.097–3.860, p = 0.017). The presence of colorectal polyps 
and age in the adjusted model were established to be inde-
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pendent risk factors for having thyroid nodules (p = 0.025 
and p = 0.007, respectively). Conclusion: These results may 
support the presence of other common mechanisms in the 
development of these two pathologies other than insulin re-
sistance and hyperinsulinemia. © 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
Colorectal polyps and thyroid nodules are common 
disorders, which are linked independently to hyperinsu-
linemia and the metabolic syndrome (Mets). Any direct 
association between these two entities is not clear.
Limited studies have reported the association between 
colorectal polyps and thyroid nodules. In a study by Du-
ran et al. [1], thyroid nodules were demonstrated to be 
more prevalent in subjects with colonic polyps. In that 
study, the components of Mets and insulin levels were not 
included in the analyses. A study by Park et al. [2] dem-
onstrated that thyroid nodules were associated with co-
lonic polyps in subjects with BMI > 25, but not in subjects 
with BMI < 25.
Mets is defined as a cluster of abnormalities, which is 
associated with cardiovascular risk and is comprised of 
abdominal obesity, abnormal glucose tolerance, dyslipid-
emia, insulin resistance (IR), and hypertension [3]. In 
many studies, Mets has been associated with some can-
cers in adults [4]. The molecular mechanisms and patho-
physiology of this syndrome have not been completely 
resolved. However, some of the carcinogenic effects are 
attributed to IR and hyperinsulinemia.
It is known that insulin uses the same signaling path-
ways with the insulin-like growth factor-1 (IGF-1) recep-
tor. In peripheral tissues, insulin binds to the insulin recep-
tor, thus leading to intracellular phosphorylation of pro-
teins. Different tissues have different sensitivities to insulin 
depending on the number of receptors on the cell mem-
brane. Increased insulin levels lead to an increase in levels 
of free IGF-1 and decreased production of IGF-1-binding 
proteins [5]. Insulin displays a mitogenic effect via increas-
ing DNA synthesis and decreasing apoptosis [6].
Obesity and IR increase the risk of colon cancer. Ad-
enomatous colon polyps are considered to be precancer-
ous lesions. The effects of increased insulin and IGF-1 
levels on cellular proliferation have been accused to be a 
potential risk for the development of colon cancer [7, 8]. 
Some studies have shown an increased prevalence of 
colorectal adenomas in Mets [9–14].
Our group has previously demonstrated a relationship 
between IR and thyroid volume (TV) together with the 
formation of thyroid nodules [15]. This has been attrib-
uted to high levels of insulin in the circulation. IGF-1-de-
pendent mechanisms have also been partially accused 
[15, 16]. Thus, a probable association between thyroid 
nodules and colorectal polyps has gained our interest due 
to common physiological mechanisms.
In the present study, we aimed to analyze the preva-
lence of thyroid nodules in subjects with and without 
colorectal polyps. The secondary aim was to establish the 
prevalence of Mets and its parameters in both disorders 
and ascertain whether IR and hyperinsulinemia are com-
mon underlying pathophysiological mechanisms.
Subjects and Methods
Prior to the study, a statistical power calculation revealed that 
at least 160 cases would be sufficient with 85.72% reliability. We 
included 105 subjects (71 males, 34 females) who were diagnosed 
as having a colorectal polyp by total colonoscopy between January 
2009 and April 2010. As the control group, we included 68 subjects 
(28 males, 40 females) who underwent total colonoscopy in the 
same time period with no visualized polyps.
Exclusion criteria were a previous history of any thyroid dis-
ease, including subclinical or overt hypo-/hyperthyroidism, previ-
ous use of levothyroxine; antithyroid drugs; any drug that can in-
terfere with the thyroid function tests, previous use of oral anti-
diabetic drugs, any previous history of radiotherapy or surgery to 
the head and neck, positive thyroid autoantibodies, kidney and 
hepatic insufficiency or abnormal laboratory results, hypercorti-
solemia, pregnancy, lactation, and a previous history of a neuro-
logical or psychiatric disease.
Criteria of the National Cholesterol Education Program 
(NCEP) Adult Treatment Panel III (ATP III) were used in evaluat-
ing the presence of Mets in the participants. A patient having at 
least three positive values out of five in the NCEP ATP III criteria 
was diagnosed as Mets [17]. Subjects with a blood pressure ≥130/85 
mm Hg or those using antihypertensive drugs were recorded as 
being hypertensive. Subjects with a fasting blood glucose (FBG) 
≥100 mg/dL or those with a glucose value ≥140 mg/dL at the 120th 
min of 75 g glucose load were recorded as having abnormal glucose 
tolerance. Subjects with an FBG ≥126 mg/dL or those with a glu-
cose value ≥200 mg/dL at the 120th min of 75 g glucose load were 
recorded as being diabetic.
Body weight was measured to the nearest kilogram and height 
to the nearest 0.1 m simultaneously with the measurement of the 
waist circumference (WC), which took place with a tape at the um-
bilical site. BMI was calculated by dividing the weight in kilograms 
to the height in meters squared. All anthropometric measurements 
were performed by the same investigator to avoid interobserver 
variability. We also measured the patients’ blood pressure with a 
sphygmomanometer after the patient had rested for at least 30 min.
A blood sample was collected from each patient for analysis of 
fasting plasma glucose (glucose oxidase method; Roche Diagnos-
tics GmbH, Mannheim, Germany), insulin (chemiluminescent as-
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say; Bio-DPC Diagnostic Products Corporation, Los Angeles, 
USA, via Immulite 2000), triglyceride, high-density lipoprotein 
(HDL) cholesterol (Hitachi Modular systems; Roche Diagnostics 
GmbH, Mannheim, Germany), TSH (immunochemiluminescent 
assay; Bio-DPC Diagnostic Products Corporation, Los Angeles, 
USA, via Immulite 2000). We performed Tg-ab and TPO-ab mea-
surements by ICMA (Immulite 2000; Siemens). In addition, a 75-g 
oral glucose tolerance test was performed to obtain the glucose 
levels at the 120th min for each patient. The homeostasis model for 
assessment of IR (HOMA-IR) was calculated by the formula fast-
ing plasma glucose (mg/dL) × fasting insulin (µU/mL) / 405 [18].
The same investigator performed thyroid ultrasonography 
(Logiq 5 Pro; GE Medical Systems, WI, USA) with a 10 MHz probe. 
We evaluated the presence of a thyroid nodule and calculated the 
TV in mL by the formula (depth × width × length × π) / 6 [19]. 
Thyroid ultrasonography was performed within 1 month of the 
initial colonoscopy.
Smoking and drinking habits together with the pathology of the 
colorectal polyp (adenomatous, hyperplastic, mixed) were record-
ed. Subjects with detected thyroid nodules were offered fine-nee-
dle aspiration cytology if indicated by the researcher.
Statistical Analysis
We used the SPSS for Windows v. 16.0 (Statistical Package for 
Social Sciences, Chicago, IL, USA) software program for the statis-
tical analysis. We used the Shapiro-Wilk and Levene tests for con-
firmation of the normality and homogeneity of variances of our 
data and the χ2 test to compare the ratios between the groups, the 
independent samples t test to compare the means between the 
groups, and the Mann-Whitney U test for comparing the means of 
nonparametric values. We performed a logistic regression analysis 
to identify independent variables. A p value of < 0.05 was defined 
as being statistically significant.
Results
We included 105 subjects (71 males, 34 females) who 
underwent total colonoscopy between January 2009 and 
April 2010 and in whom colorectal polyps were detected. 
As the control group, we included 68 subjects (28 males, 
40 females) who underwent colonoscopy, which was re-
ported as normal in the same time period. A total of 99 
male (57.2%) and 74 female (42.8%) subjects was en-
rolled.
Prevalence of Thyroid Nodules and Analyses of Risk 
Factors in the Study Group
The prevalence of thyroid nodules in subjects with 
colorectal polyps was significantly higher than in subjects 
without polyps (55/105 [52.9%] vs. 24/68 [35.3%] p = 
0.017) (Fig. 1). Compared to subjects with no colorectal 
polyps, in subjects with colorectal polyps, we established 
a significant increase in the odds of having thyroid nod-
ules (OR 2.05; 95% CI: 1.097–3.860, p = 0.017).
The prevalence of thyroid nodules was similar in male 
and female subjects (45/99 [44.9%] vs. 35/74 [47.3%], 
p = 0.760).
A total of 112 subjects were ≥50 years of age, and 61 
subjects were < 50 years. The prevalence of thyroid nod-
ules was significantly higher in subjects ≥ 50 years com-
pared to those < 50 years (62/112 [55.4%] vs. 17/61 
[28.3%], p = 0.001). Compared to subjects < 50 years, in 
subjects ≥50 years, we demonstrated a significant in-
crease in the odds of having thyroid nodules (OR 3.13, 
95% CI: 1.59–6.15, p = 0.001). However, the prevalence of 
colorectal polyps was similar in both age groups.
The prevalence of thyroid nodules was higher in sub-
jects with abnormal glucose tolerance (i.e., diabetes or 
prediabetes) compared to those with normal glucose tol-
erance (39/71 [54.9%] vs. 40/102 [39.6%], p = 0.048). 
Compared to subjects with normal glucose tolerance, in 
subjects with abnormal glucose tolerance, we established 
a significant increase in the odds for developing thyroid 
nodules (OR 1.85, 95% CI: 1.01–3.43, p = 0.048). Again, 
the prevalence of colorectal polyps was similar in subjects 
with abnormal glucose tolerance compared to normal 
glucose tolerance.
The prevalence of thyroid nodules in subjects with hy-
pertension was significantly higher than in normotensive 
subjects (30/52 [57.7%] vs. 49/121 [40.8%], p = 0.047). 
Compared to normotensive subjects, in hypertensive 
subjects, we determined a significant increase in the odds 
for developing thyroid nodules (OR 1.9, 95% CI: 1.02–
120
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Fig. 1. Bar charts displaying the presence of thyroid nodules in 
subjects with and without colonic polyps.
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3.80, p = 0.047). Subjects in the colorectal polyp group 
were prone to be more hypertensive compared to the con-
trol group. This comparison did not reach statistical sig-
nificance (37/105 [35.2%] vs. 15/68 [22.1%], p = 0.089).
The prevalence of thyroid nodules was similar in sub-
jects with triglyceride levels ≥150 mg/dL compared to 
those < 150 mg/dL (48/110 (44.0%) vs. 31/63 (50.8%), p = 
0.529). Again, the presence of colorectal polyps was simi-
lar in both triglyceride groups.
The presence of thyroid nodules and colorectal polyps 
was similar in subjects with HDL values, and WC was 
lower than the values determined by the NCEP ATP III 
criteria compared to those with normal values (i.e., HDL 
≥40 mg/dL and WC < 102 cm for male and HDL ≥50 mg/
dL and WC < 88 cm for female subjects) (Table 1).
We performed a logistic regression analysis to define 
the independent variables for the presence of thyroid 
nodules. The regression models were adjusted for the 
presence of colorectal polyps, age group, abnormal glu-
cose tolerance, and hypertension. Presence of colorectal 
polyps and age were established to be independent risk 
factors for having thyroid nodules (p = 0.025 and p = 
0.007, respectively).
The prevalence of thyroid nodules did not differ be-
tween smokers and nonsmokers. Again, the prevalence of 
thyroid nodules was similar in all 3 types of colorectal 
polyps (adenomatous, hyperplastic, and mixed).
Prevalence of Mets in the Study Group
The presence of Mets was similar in the colorectal pol-
yp and control groups (39/105 [37.1%] vs. 25/68 [37.3%], 
p = 0.982). A total of 39 subjects with colon polyps were 
Mets(+). Out of these 24 had documented thyroid nod-
ules (61.5%). A total of 66 subjects with colon polyps were 
Mets(–). Out of these, 31 (48.5%) had thyroid nodules. 
The comparison did not reach statistical significance (p = 
0.224). The sex distribution was detected to be similar in 
Mets(+) and Mets(–) subjects with colorectal polyps. 
Table 1. Risk factors for thyroid nodules in unadjusted and adjusted models
Nodule (–),
n (%)
Nodule (+),
n (%)
Total p value
unadjusted
p value
adjusted
Colorectal polyps
No 44 (64.7) 24 (35.3) 68 0.017* 0.025*
Yes 50 (47.1) 55 (52.9) 105
Sex
Female 39 (52.7) 35 (47.3) 74 0.760 0.576
Male 54 (55.1) 45 (44.9) 99
Hypertension
No 72 (59.2) 49 (40.8) 121 0.047* 0.773
Yes 22 (42.3) 30 (57.7) 52
Abnormal glucose metabolism
No 62 (60.4) 40 (39.6) 102 0.048* 0.134
Yes 32 (45.1) 39 (54.9) 71
Age
<50 years 43 (71.7) 18 (28.3) 61 0.001* 0.007*
≥50 years 50 (44.6) 62 (55.4) 112
High triglycerides
No 32 (50.8) 31 (49.2) 63 0.529 0.977
Yes 62 (56.0) 48 (44.0) 110
Low HDL-C
Yes 40 (50.0) 40 (50.0) 80 0.359 0.218
No 54 (57.6) 39 (42.2) 93
Increased WC
No 53 (58.9) 39 (41.1) 92 0.221 0.684
Yes 40 (49.4) 41 (50.6) 81
Low HDL-C: <50 mg/dL for female and <40 mg/dL for male subjects; increased WC: >102 cm for male subjects and >88 cm for female 
subjects; high triglycerides: ≥150 mg/dL. * Statistically significant.
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However, the age group was higher in Mets(+) subjects 
with colorectal polyps compared to Mets(–) subjects with 
colorectal polyps (44.6 vs. 19.4%, p = 0.016).
Out of the total 173 (46.2%) subjects, 79 were demon-
strated to have thyroid nodules. Out of these, 44 (55.0%) 
had a uninodular goiter, and 35 (45.0%) had a multinod-
ular goiter. The prevalence of Mets was higher in subjects 
with a documented thyroid nodule compared to subjects 
without a thyroid nodule. This analysis did not reach sta-
tistical significance (34/79 [43.0%] vs. 30/94 [31.9%], p = 
0.205). The prevalence of Mets did not differ between 
subjects with uninodular and multinodular goiter (21/44 
[47.7%] vs. 13/35 [38.2%], p = 0.365).
Comparison of Means
A comparison of some anthropometric, laboratory, 
and thyroid parameters of the study groups are presented 
in Table 2. The mean BMI, FBG, insulin, HOMA IR, and 
triglyceride levels were similar in both the colorectal pol-
yp and control groups. The TV was higher (16.38 ± 11.16 
vs. 12.92 ± 7.33 mL, p = 0.027), the low-density lipopro-
tein cholesterol (LDL-C) was higher (132.36 ± 34.57 vs. 
121.25 ± 30.71 mg/dL, p = 0.032), and the TSH level was 
lower (1.40 ± 0.84 vs. 1.72 ± 0.97 mIU/L, p = 0.026) in the 
colorectal polyp group compared to the control group. 
The mean age, FBG, and TV were significantly higher in 
subjects having a documented thyroid nodule compared 
to those without a thyroid nodule (55.39 ± 9.18 vs. 51.75 
± 11.15 years, p = 0.032; 108.49 ± 28.06 vs. 100.42 ± 19.88 
mg/dL, p = 0.029; 18.13 ± 13.26 vs. 12.36 ± 4.88 mL, p < 
0.0001). The mean BMI, insulin, HOMA-IR, triglycer-
ides, HDL-C, and LDL-C were similar in subjects with 
and without thyroid nodules.
Discussion
Colorectal polyps are known to be precursors of colon 
adenocarcinoma together with other known risk factors 
such as age, high-lipid and low-fiber diet, hyperinsu-
linemia, and IGF-1 [9, 10]. Mets is an endocrinopathy in 
which IR plays the central role and links abdominal obe-
sity, glucose tolerance defects, lipid anomalies, hyperten-
sion, and coronary artery disease. Furthermore, Mets is 
known to be related to some cancers of adulthood. Many 
studies have demonstrated an increased prevalence of 
colorectal adenomas in subjects with Mets. Hyperinsu-
linemia, IR, high-fat and low-fiber diet, changes in the 
microbiota, and increased IGF-1 levels have been accused 
in this relationship [9–11, 20, 21].
Recent studies have demonstrated increased TV and 
higher prevalence of thyroid nodules in subjects with 
Mets [15]. This has been attributed to high insulin levels 
and partially to IGF-1-related mechanisms.
According to our results, age and the presence of 
colorectal polyps were determined to be independent risk 
factors for thyroid nodules, and TV is larger in subjects 
with colorectal polyps. We failed to correlate our findings 
with Mets and its components in subjects with colorectal 
polyps. The prevalence of thyroid nodules was associated 
with two of the components of Mets (i.e., glucose metab-
olism defect and hypertension), which were determined 
to be dependent risk factors.
Mets and hyperinsulinemia have been implicated as 
factors in the development of both thyroid nodules and 
colorectal polyps [11, 12, 15]. However, in our study, the 
prevalence of Mets and its components was similar in 
subjects with and without colorectal polyps. We also 
failed to demonstrate higher insulin levels and HOMA-IR 
scores in these subjects. This finding was not consistent 
with some previously reported studies. Morita et al. [11] 
demonstrated that Mets and its parameters were associ-
ated with the development of colorectal polyps in a study 
including 756 subjects with colorectal polyps and 1,751 
controls. Similarly, Kim et al. [12] established that the 
prevalence of Mets was significantly higher in subjects 
with colorectal adenomas compared to a control group. 
Lee et al. [14] demonstrated that the development risk of 
colorectal adenomas was higher even in subjects with 
only one component of Mets. The relatively low number 
of participants in the present study may be a reason for 
Table 2. Comparison of some anthropometric parameters between 
the groups
Colorectal polyp
group
Control group p
Age, years 54.48±10.01 51.87±10. 86 0.107
BMI 28.88±7. 66 27.99±4. 06 0.425
TV, mL 16.38±11.16 12.92±7.73 0.027*
FBG, mg/dL 101.88±23.95 107.25±24.54 0.155
Insulin 9.54±4.64 10.52±8.10 0.315
HOMA-IR 2.43±1.33 2.84±2.88 0.204
LDL-C, mg/dL 132.36±34.57 121.25±30.71 0.032*
Triglycerides, mg/dL 144.92±85.59 143.34±89.17 0.907
TSH 1.40±0.84 1.72±0.97 0.026*
Values are presented as mean ± standard deviation. * Statistically sig-
nificant.
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not documenting the increased prevalence of Mets in 
subjects with colorectal polyps.
Pathophysiological mechanisms other than hyperin-
sulinemia have been demonstrated in the development 
of colorectal polyps. IGF-1 plays important roles in 
growth and cellular metabolism. IGF-1 also inhibits 
apoptosis. Normal and cancerous colorectal epithelium 
express IGF-1 receptors. Saubry et al. [10] previously 
demonstrated that IGF-1 levels were correlated with the 
development of colorectal adenomas. Another substance 
involved in the pathogenesis of colorectal polyps is glu-
cose-dependent insulinotropic peptide (GIP), which 
stimulates the secretion of insulin from the pancreas and 
leads to lipogenesis. Sasaki et al. [22] analyzed the rela-
tionship between GIP and the development of colorectal 
adenomas. Fasting GIP levels, FBG, triglycerides, insulin 
levels, and HOMA-IR were significantly higher in the 
disease group compared to the control group. In this 
study, multiple logistic regression revealed that the high-
est quartile of fasting GIP levels was associated with a 
significantly higher risk of colorectal adenoma (OR, 2.1; 
95% CI, 1.08–3.96; p = 0.01) in comparison with the low-
est quartile.
It is known that increased epithelial proliferation oc-
curs in subjects with acromegaly, which is correlated with 
IGF-1 and growth hormone levels. The pathogenesis of 
colonic lesions in acromegaly is not well understood. A 
study by Foltyn et al. [23] demonstrated that hyperinsu-
linemia, IR, and colonic lesions were significantly higher 
in a cohort of 40 acromegalic subjects. In the same study, 
they demonstrated that in subjects with multiple colonic 
polyps, the number of hyperplastic and adenomatous 
polyps were correlated with HOMA-IR.
In the present study, the prevalence of Mets was non-
significantly higher in subjects with thyroid nodules 
compared to those without thyroid nodules. The compo-
nents of Mets that were associated with the prevalence of 
Mets were hypertension and abnormal glucose metabo-
lism. However, in the adjusted models, these compo-
nents were not defined to be independent. Age and the 
presence of colorectal polyps were defined as the inde-
pendent variables associated with thyroid nodule preva-
lence. Supporting this finding, the thyroid volume was 
significantly larger in subjects with colorectal polyps 
compared to the control group. Studies associating 
colorectal polyps and thyroid nodules are limited. Simi-
lar to our findings, a study by Duran et al. [1] detected 
that thyroid nodules were more prevalent in subjects 
with colorectal polyps. In another study, Park et al. [2] 
demonstrated a significant correlation between colorec-
tal polyps and thyroid nodules only in subjects with a 
BMI ≥25. This relationship did not exist in subjects with 
a BMI ≤24.9.
It is known that the insulin/IGF-1 pathway modulates 
thyroid gene expression and acts as a cofactor for thyro-
cyte proliferation and differentiation. It has been report-
ed that in cell cultures, TSH has mitogenic and antiapop-
totic effects with insulin. IGF-1 and insulin receptors 
have been demonstrated in thyrocyte cultures. In addi-
tion, the high goiter prevalence in subjects with acromeg-
aly shows the activity of IGF-1 in vivo as a co-mitogenic 
factor. Rezzonico et al. [24] reported that the TV was 
higher, and the risk of development of thyroid nodules 
was higher in subjects with IR.
The main limitation of our study was the relatively 
small number of participants enrolled. This may have had 
an impact on our findings regarding the prevalence of 
thyroid nodules in the different subgroups related to age, 
glucose intolerance, blood pressure, triglycerides, and 
smoking habits. A large prospective cohort would be 
more meaningful with regard to these subclassifications. 
Despite this limiting factor, our study was an interven-
tional study in which the thyroid ultrasonography was 
performed concurrently with the total colonoscopy, and 
all anthropometric and ultrasonographical evaluations 
were performed by the same investigator.
Conclusion
Our findings support the presence of common mecha-
nisms other that IR and hyperinsulinemia in the develop-
ment of these two entities, such as IGF-1. Our findings 
need to be proven with high-scale prospective studies in-
cluding IGF-1 assays.
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